Understanding Lung Deposition of Alpha-1 Antitrypsin in Acute Experimental Mouse Lung Injury Model Using Fluorescence...

Area of Science:

• Pharmacology and Therapeutics
• Pulmonary Medicine
• Biochemistry

Background:

• Alpha1-antitrypsin (AAT) deficiency causes emphysema, typically treated with intravenous plasma-derived AAT.
• Inhalation offers a potentially more effective and convenient administration route for AAT augmentation therapy.
• Recombinant AAT (rAAT) is being investigated as an alternative therapeutic agent.

Purpose of the Study:

• To evaluate the delivery and efficacy of intratracheally administered recombinant AAT (rAAT) in the lungs of mice.
• To determine if rAAT reaches sites of neutrophil elastase activity in the lungs.
• To provide data for predicting human inhalation dosage for rAAT therapy.

Main Methods:

• Utilized ¹²⁵I-radiolabeled rAAT to assess pharmacokinetics and tissue distribution.
• Employed fluorophore-conjugated rAAT (rAAT-Alexa488) to visualize lung distribution.
• Used NE680, a neutrophil elastase substrate, to confirm rAAT's inhibitory activity at the site of action.

Main Results:

• Demonstrated that intratracheally delivered rAAT successfully reached lung locations where neutrophil elastase was present.
• Confirmed rAAT's ability to inhibit neutrophil elastase activity within the lung tissue.
• Provided quantitative data on rAAT activity relative to dose at the target site.

Conclusions:

• Intratracheal administration of rAAT leads to efficacious levels at the site of action in the lungs.
• The study validates the potential of inhaled rAAT as a therapeutic strategy for AAT deficiency.
• Findings support the use of these methods to predict optimal human inhalation dosage for rAAT.